Life Sciences

  • February 25, 2026

    Online Abortion Pill Provider Illegally Ships To Texas, AG Says

    Texas Attorney General Ken Paxton sued Aid Access, its founder and a California doctor in state court Tuesday alleging they operate an "abortion-by-mail enterprise" that ship abortion-inducing drugs to Texas residents, which is endangering the lives of unborn children and their mothers. 

  • February 25, 2026

    White House Cites Fraud, Freezes $259M In Minn. Medicaid

    The Trump administration on Wednesday said it would hold back $259.9 million in Medicaid funding for Minnesota as part of what it called an unprecedented effort to combat fraud in programs that support low-income families.

  • February 25, 2026

    Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity

    When the Federal Circuit revived the University of Pennsylvania's gene therapy patent last week, it provided a bright-line rule that's often missing in the debate over patent eligibility, attorneys say.

  • February 25, 2026

    $17.9M Drug Price-Fixing Deal Advances Despite Objections

    A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.

  • February 25, 2026

    Birth Control Shot Plaintiffs Lose Mid-Case Appeal Bid In Del.

    The Delaware Supreme Court has refused to hear an interlocutory appeal in product liability litigation over the contraceptive injection Depo-Provera, leaving in place a set of case-management orders designed to streamline what is expected to become hundreds of lawsuits in the state.

  • February 25, 2026

    NJ Judge Trims J&J And Neutrogena Benzene Suit

    A New Jersey federal judge has slashed state and common law claims in a multistate proposed class action alleging that acne cream produced by Johnson & Johnson Consumer Inc. and Kenvue Inc. contained a cancer-causing chemical without warning labels, saying the buyers' claims missed "a step" and were "circular."

  • February 25, 2026

    9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case

    The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement between the companies did not cover insulin products Eli Lilly made using a certain yeast expression technology.

  • February 25, 2026

    Philly Says PBMs Can't Exit Suit Over Opioid Crisis

    The city of Philadelphia on Wednesday defended its lawsuit against CVS Health Corp. and other pharmacy benefit managers over allegedly fueling the opioid crisis, urging a Pennsylvania federal judge to reject the PBMs' arguments that they should be let out of the litigation for lack of a valid legal claim.

  • February 25, 2026

    Hagens Berman Fights Fee Demand Amid Misconduct Claims

    Hagens Berman Sobol Shapiro LLP has blasted as premature a bid from drugmakers in Pennsylvania federal court calling for the firm to cover the fees and costs of a special master who alleged the firm committed misconduct in product liability actions over the morning sickness drug thalidomide.

  • February 25, 2026

    Life Sciences Group Of The Year: Davis Polk

    Davis Polk & Wardwell LLP attorneys advised Intra-Cellular Therapies Inc. on its $14.6 billion sale to Johnson & Johnson, guided Endo Inc. through its $6.7 billion merger with Mallinckrodt PLC and advised Novo Nordisk in its proposed $9.1 billion acquisition of Metsera, earning it a spot among the 2025 Law360 Life Sciences Groups of the Year. 

  • February 25, 2026

    Taft Adds 5-Person IP Team From McAndrews Held

    Taft Stettinius & Hollister LLP announced on Wednesday that it has hired a group of four attorneys and one patent agent from McAndrews Held & Malloy Ltd. in the Chicago, Minneapolis and West Palm Beach, Florida, offices.

  • February 25, 2026

    Budtender Alleges Dispensary Gives Tips To Managers

    A proposed class of budtenders is suing an Illinois dispensary and its management company, saying they violate state and federal labor law by pooling tips and distributing them to managers as well as the budtenders.

  • February 25, 2026

    Moderna's Damages Expert Limited In March Patent Trial

    Moderna's damages expert was blocked from offering testimony about what a reasonable royalty would be in a suit alleging its COVID-19 vaccine infringed a rival's patents, after a federal judge found that part of the testimony wasn't reliable.

  • February 25, 2026

    Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline

    Novo Nordisk said on Wednesday it is partnering with Vivtex Corp. on a deal worth up to $2.1 billion to develop drugs for obesity and related conditions, pressing ahead with a weight loss-drug franchise that has delivered rapid growth alongside regulatory scrutiny and courtroom clashes.

  • February 24, 2026

    9th Circ. Grants Atty Fee Appeal In Eye Drop Pricing Suit

    District courts cannot reduce fee awards to attorneys based on a firm's size, the Ninth Circuit ruled in a published opinion Tuesday, sending a case back to a California federal court to recalculate attorney fees awarded to a "small" firm that represented wholesalers in a Robinson-Patman Act suit against eye drop manufacturers.

  • February 24, 2026

    Ariz., Calif. Lead Suit Over 'Senseless' HHS Vaccine Overhaul

    Arizona and California are leading a coalition of states challenging the U.S. Department of Health and Human Services' decision to cut vaccine recommendations for American children, alleging in a lawsuit Tuesday that the "unprecedented attack" stems from HHS Secretary Robert F. Kennedy Jr.'s "unscientific hostility to vaccines."

  • February 24, 2026

    Ex-Med School Dean Claims Fla. College Broke Work Contract

    The former dean of Florida International University's medical school told a state court that the university breached his employment contract by refusing to pay him the salary promised in their agreement and undermined his independence.

  • February 24, 2026

    Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit

    Two former Mallinckrodt executives have escaped the only remaining claims they faced in an investor suit tied to the company's 2023 bankruptcy and share cancellations after a New Jersey federal judge said he made a "clear error" keeping them in the suit last year.

  • February 24, 2026

    6th Circ. Affirms Dismissal Of Sotera Toxic Gas Investor Suit

    The Sixth Circuit on Tuesday affirmed a lower court's dismissal of an investor lawsuit accusing Sotera Health Co. of concealing the carcinogenic nature of a gas used at its sterilization plants, finding Sotera did not make any actionable false or misleading statements to investors.

  • February 24, 2026

    Lindis Decries Erasing $50M Verdict Over Inequitable Conduct

    A Delaware federal judge wrongly overruled Lindis Biotech's $50 million infringement verdict against Amgen by falsely concluding an inventor intended to deceive the patent office during prosecution, the German company has told the Federal Circuit.

  • February 24, 2026

    High Court Won't Stay Dow Corning Breast Implant Fund Row

    The U.S. Supreme Court on Tuesday denied a request to stay a lower court's order permanently wiping out the claims of more than 2,600 Koreans who said they were failed by how the settlement was structured, as they were given notice only in English regarding their claims.

  • February 24, 2026

    Novo Nordisk Wants Expert Cut From Hospital Insulin Pen Suit

    Novo Nordisk on Tuesday asked a Connecticut federal judge to remove an expert witness's report and related testimony from an insulin pen contamination lawsuit, hoping a hospital's entire case fails once the expert's opinions are blocked.

  • February 24, 2026

    Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules

    A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.

  • February 24, 2026

    Philips Unit Escapes CPAP Machine Whistleblower Case

    Philips Respironics, a unit of Koninklijke Philips NV, fended off a whistleblower suit alleging it provided kickbacks to CPAP suppliers that bought its products, with a Pennsylvania federal judge ruling that a former Philips manager failed to show that the company willfully engaged in illegal conduct.

  • February 24, 2026

    Biotech Co. Moves To Dismiss LSD Trade Secret Suit

    A biotechnology company accused of having lifted trade secrets regarding clinical trials of potential LSD treatments for psychiatric disorders asked a Delaware federal judge Monday to dismiss or narrow the suit, which it says was brought by a "disgruntled former vendor."

Expert Analysis

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.